Ajan Reginald is the chief executive officer of Celixir (formerly Cell Therapy Limited). Ajan Reginald is a biotechnology entrepreneur with a medical & dentistry background. A keen Hockey player, Ajan also managed Hockey for Hero’s.

Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans.

Celixir is a British biotechnology company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need. Celixir’s unique, world-class technology platform drives in-house discovery and has created a pipeline of 20 tissue-specific regenerative medicines, an unprecedented feat in the field of regenerative medicine.

Celixir’s pipeline is led by their investigational cardiac regenerative medicine, HeartcelTM which is designed to treat patients with ischaemic heart disease undergoing coronary artery bypass graft. Alongside HeartcelTM, Celixir has late-stage development medicines in orthopaedics and mild to moderate heart failure as well as early phase development medicines in type 1 diabetes and oncology.

Ajan previously served as the Global Head of Emerging Technologies and Business Development Director at Roche where he oversaw the identification, acquisition and development of the next generation of breakthrough biopharma technologies and products. He joined Roche as a Business Development Director for Roche Pharma, where he led merger & acquisitions teams and major licensing transactions including a $1.3B licensing transaction with Alnylam. He is a former Boston Consulting Group Consultant and a Fulbright Scholar, with an MSc in Experimental Therapeutics.

– Old Biography –

Ajan Reginald (See Ajan’s Celixir Biography) Executive Director Cell Therapy Limited (CTL): CTL develops cellular medicines to combat life threatening and life altering diseases. Ex-Global Head of Emerging Technologies, Roche Ex-Business Development Director, Roche Consultant, Boston Consulting Group Kellogg School of Management – Fulbright Scholar University of London.

Ajan Reginald was a visiting research fellow at BMC, developing BMC educational programs and lecturing the core BioPharma course. Ajan co-founded Cell Therapy Ltd (CTL) in 2009 with Professor Sir Martin Evans, Nobel Laureate 2007. CTL is award winning biotech company developing stem cell therapeutics with clinical programs starting in 2012.

An experienced entrepreneur and life sciences professional. Ajan was Global Head of Emerging Technologies at Roche Pharmaceuticals in which he led efforts to identify and commercialise the best breakthrough life science technologies including a focus on Stem cells.

Prior to Emerging Technologies, Ajan completed over 30 licensing and acquisition transactions a Business Development Director at Roche.

Previously Ajan worked with the Boston Consulting Group in the USA & Zurich as a member of both the Life Sciences Practice Area and Intellectual Property Group. Ajan is a Fulbright scholar, graduate of London Hospital School of Medicine and Dentistry and MBA from the Kellogg Business School at Northwestern University.

breakthrough cellular medicines that treat life threatening / life changing diseases. In 2014, Cell Therapy completed Phase II clinical trials in End-stage heart failure with Phase III trials starting in 2015.  The company’s pipeline also includes consists of 2 more disease specific products in Phase II trials for Orthopaedic and Dermatology indications.

Ajan is an inventor of CTL’s core technology and tissue specific regenerative medicine products. And leads the company’s commercial and operational activities.

Ajan was Roche’s Global Head of Emerging Technologies overseeing the identification, acquisition and development of the next generation of breakthrough Biopharma technologies and products. He joined Roche as Business Development Director in Roche Pharma, where he led M&A teams and major licensing transactions including the $1.3B licensing transaction with Alnylam.

Prior to Roche, Ajan was a consultant with the Boston Consulting Group and received a MBA from Kellogg Business school, Northwestern University where he was awarded the Biotechnology scholarship. In 2002, he was awarded the UK Fulbright Scholarship.

LinkedIn Profile – https://uk.linkedin.com/pub/ajan-reginald/12/885/86a

Website – http://ajanreginald.com/

Twitter – https://twitter.com/ajanreginald

Cell Theraphy – http://celltherapyltd.com/leadership.html

Facebook – https://www.facebook.com/ajan.reginald

Pintrest – https://uk.pinterest.com/ajanreginald/

Ajan Reginald is recognised also for his passion for Hockey.  Ajan Reginald and the Celixir team sponsored Hockey For Heroes.  Ajan Reginald’s background has included dentistry which lead on to a career in biotechnology as a biotechnology entrepreneur.

Ajan Reginald In The Press

Cell Therapy Lt’s CEO Ajan Reginald talks to TPL’s Katie Osborne
Ajan Reginald on Crunchbase
How one cell therapy company is driving a paradigm shift in medical practice
An interview with Ajan on Phacilitate
Ajan on AngelList
Can We Get Rid Of EpiPen Price Gouges With Science? An Interview With Ajan Reginald